Suzhou Ausaikang Biopharmaceutical

Suzhou Aosaikang Biopharmaceutical is a specialized biotechnology subsidiary of Jiangsu Aosaikang Pharmaceutical (AskPharma) focused on the discovery and development of innovative biologics. Based in the Suzhou Industrial Park, the company concentrates on oncology and ophthalmology, utilizing proprietary antibody engineering and fusion protein platforms such as Smart-Kine. Its lead candidate, ASKB589, is a humanized anti-Claudin 18.2 monoclonal antibody currently in Phase 3 clinical trials for gastric and gastroesophageal junction cancers. The company also advances novel immunotherapy candidates like ASKG915, a PD-L1/IL-15 fusion protein, and ASKG712, a bispecific fusion protein for retinal diseases. Suzhou Aosaikang plays a critical role in AskPharma's strategic transition toward becoming an innovation-led biopharmaceutical company. Through its integrated R&D capabilities, the firm aims to address significant unmet medical needs in the global market.